Add BrightSurf on Google Email

European College of Neuropsychopharmacology


Severe mental illness linked to higher dementia risk even at young age, and greater stroke risk earlier in life

A large study found a significant association between severe mental illness and dementia at every age, with adults aged 30-39 showing a 20-fold increased risk of dementia. The study also found a higher risk of stroke in early and middle adulthood, particularly in those with severe mental illness.

SourceEuropean College of Neuropsychopharmacology·JournalEuropean Neuropsychopharmacology·TypeObservational study·DateAug 17, 2026

Where are the biomarkers in psychiatry? Psychiatrists take first steps towards establishing a structure for objective mental health diagnosis

Researchers are creating a centralized database to standardize and share biomarker research in anxiety disorders, depression, and psychosis. This initiative aims to advance precision psychiatry by integrating biological, behavioral, and clinical data for more accurate diagnosis and treatment.

Study confirms that people with ADHD can be more creative. The reason may be that they let their mind wander

A study confirms that people with ADHD can be more creative due to their tendency to let their minds wander. The research found that individuals with ADHD symptoms showed higher scores on creative achievements and were associated with greater mind wandering, particularly deliberate mind wandering.

SourceEuropean College of Neuropsychopharmacology·TypeObservational study·DateOct 10, 2025

Weight-loss drug semaglutide reduces cocaine use in rats: Suggests possible first pharmacological treatment for human cocaine dependency

Semaglutide significantly reduces cocaine-seeking behavior in rats by 26%, with a 62% drop in seeking after abstinence. This finding suggests semaglutide's potential as a treatment for human cocaine dependency, currently lacking effective pharmacological options.

SourceEuropean College of Neuropsychopharmacology·JournalEuropean Neuropsychopharmacology·TypeExperimental study·DateSep 3, 2025

Study shows alcohol-dependent men and women have different biochemistries, so may need different treatments

A new study confirms that hormonal and biochemical factors affect alcohol dependence in men and women differently, implying the need for sex-specific treatments. Researchers found associations between hormone levels and treatment outcomes, highlighting the importance of considering gender differences in treating alcoholism.

Study shows psychedelic drug psilocybin gives comparable long-term antidepressant effects to standard antidepressants, but may offer additional benefits

A 6-month study found that psilocybin offered similar improvements to SSRI escitalopram in depressive symptoms, but with greater social functioning and psychological connectedness. Psilocybin may offer an alternative for those not responding to SSRIs, but its benefits are still being studied.

SourceEuropean College of Neuropsychopharmacology·TypeRandomized controlled/clinical trial·DateSep 21, 2024

First international expert and patient collaboration recommends changes to development, assessment, and approval of mental health medicines for young people

A new study published in The Lancet Psychiatry calls for improved processes for developing medicines for children and young people. Experts and patients collaborated to define new parameters for the development of these medicines.

SourceEuropean College of Neuropsychopharmacology·JournalThe Lancet Psychiatry·TypeSystematic review·DateDec 7, 2023

Ketamine-related drug gives better treatment for difficult to treat clinical depression

The ESCAPE-TRD study found that esketamine nasal spray outperforms quetiapine in treating treatment-resistant major depression, with patients showing higher remission rates and reduced depressive symptoms. The results suggest esketamine as a safe and effective treatment option for those with treatment-resistant depression.

SourceEuropean College of Neuropsychopharmacology·JournalNew England Journal of Medicine·DateOct 4, 2023

Patients with clinical depression “stopped seeking treatment” during the COVID waves

The COVID-19 pandemic saw a significant decrease in hospital admissions for first-time clinical depression and recurrent depression, while outpatient treatment remained stable. This shift implies that many patients did not receive appropriate care for their condition, potentially leading to long-term quality of life loss.

SourceEuropean College of Neuropsychopharmacology·TypeObservational study·DateOct 15, 2022

Depression history written in the reactions of the brain

Researchers found that patients with more severe depression histories showed less brain activity in areas processing emotions, while those who had remitted from depression showed a normal level of activity. This suggests that serious depression may change the way the brain responds to emotion over time, or that people with stronger emo...

SourceEuropean College of Neuropsychopharmacology·JournalBiological Psychiatry Cognitive Neuroscience and Neuroimaging·TypeObservational study·DateOct 18, 2021

Psychiatric patients at increased risk of COVID-19 hospitalization and mortality

A large meta-analysis of 33 studies from 22 countries found that psychiatric patients are twice as likely to die or be hospitalized after SARS-CoV-2 infection. Patients with psychotic disorders, mood disorders, and those receiving antipsychotic or anxiolytic treatments are particularly vulnerable to COVID-19-associated mortality.

SourceEuropean College of Neuropsychopharmacology·JournalThe Lancet Psychiatry·DateJul 16, 2021

Most European countries ignore patients with severe mental illness in COVID vaccine strategy

A survey of 20 European countries found that only 4 prioritize COVID vaccinations for individuals with severe mental disorders. The authors call for coordinated action to protect these vulnerable patients. Many countries do not mention mental health in their vaccination priority guidance, leaving patients at risk.

SourceEuropean College of Neuropsychopharmacology·JournalThe Lancet Psychiatry·DateFeb 17, 2021